Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Placing and Directors' Shareholdings

27 Feb 2012 07:00

RNS Number : 1320Y
CareCapital Group plc
27 February 2012
 



 

27 February 2012

 

CARECAPITAL GROUP PLC

("CareCapital", "the Group" or "the Company")

 

Placing to Raise £1.1 million

 

Directors' Shareholdings

 

CareCapital (AIM: CARE) announces that it has conditionally placed 71,656,272 new ordinary shares in the Company ("the Placing Shares") at a price of 1.5 pence per Ordinary Share, raising gross proceeds of £1.075 million (£1.037 million net), from institutional and other investors, including the Directors of CareCapital.

 

The net proceeds of the Placing Shares are to be used to provide additional resources to capitalise on opportunities in the cancer diagnosis and treatment market, building on the Group's 28.75% stake in Advanced Proton Solutions (Holdings) Ltd - the company that is pioneering the use of Proton Beam Therapy in the UK and which has secured planning approval for its first London based centre off Moorgate in the City of London, within easy access of a number of London's major hospitals.

 

The Placing is not conditional on approval by shareholders in a general meeting since CareCapital secured shareholder approval to recapitalise the Company at its recent Annual General Meeting held on 31 January 2012. Application has been made for the Admission to AIM of the new ordinary shares issued and this is expected to become effective on 8 March 2012. The Placing Shares, on Admission to AIM will represent approximately 48.3 per cent. of the Company's enlarged issued share capital, and will rank pari passu with the existing Ordinary Shares.

 

Certain of the Directors, detailed below, participated in the Placing, which is deemed to be a Related Party Transaction pursuant to AIM Rule 13. The Director who is independent of this transaction, being Don Baladasan, considers, having consulted with the Company's Nominated Adviser, Libertas Capital Corporate Finance Limited, that the terms of the placing are fair and reasonable insofar as the Company's shareholders are concerned. The Directors' participation and resultant beneficial holdings in the Company are as follows:

 

Name of Director

New shares acquired

Total holding in the enlarged share capital of the Company

% of enlarged issued share capital

Dr Michael Sinclair

14,666,667

31,670,121

21.34

Paul Stacey

4,666,667

9,005,031

6.07

Keith Gibbs

1,666,667

1,666,667

1.12

Lord Evans of Watford

1,666,667

1,666,667

1.12

 

The Placing Shares were placed with existing and new investors by Rivington Street Corporate Finance.

 

Commenting on the fundraise, Mike Sinclair, Chairman of CareCapital, said,"The Board and management team at CareCapital have almost completed the deleveraging of the Group that was our first priority in the strategy to restore value to shareholders. Our historic core business of medical centre developments is being de-risked through the use of forward sales of pipeline developments.

 

"The Directors believe that our shareholding in Advanced Proton Solutions, a business we were instrumental in founding, could form the basis of a new division for CareCapital focused on the provision of leading edge - but clinically proven and in use - cancer diagnosis and treatment services. We hope to make further announcements on our progress in this regard during the current financial year."

 

For further information please visit www.carecapital.co.uk or contact:

 

Mike Sinclair, Chairman

Paul Stacey, Managing Director

Sandy Jamieson

Jon Levinson

Simon Hudson,

 

CareCapital Group PlcLibertas Capital Corporate Finance LimitedRivington Street

Corporate Finance

Tavistock Communications
 (NOMAD & Joint Broker)

(Joint Broker)

(Financial PR & IR)

020 7034 1949020 7569 9650

020 7562 3357

020 7920 3150

 

~ ends ~

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCXELFLLLFFBBK
Date   Source Headline
9th May 20247:00 amRNSCancellation - Advanced Oncotherapy Plc
3rd May 20248:54 amRNSFurther update on financing discussions
2nd Apr 20243:50 pmRNSFurther update on financing discussions
29th Feb 20245:19 pmRNSFurther update on financing discussions
1st Feb 20247:00 amRNSFurther update on financing discussions
9th Jan 20249:00 amRNSUpdate on Financing Discussions
23rd Oct 20237:00 amRNSUpdate on Financing and Current Financial Position
17th Jul 20237:00 amRNSRecapitalisation and funding plan, update on FSP
30th Jun 20235:00 pmRNSTotal Voting Rights
30th Jun 20237:30 amRNSSuspension - Advanced Oncotherapy PLC
30th Jun 20237:15 amRNSUpdate on financing, suspension of trading on AIM
29th Jun 20231:35 pmRNSHolding(s) in Company
29th Jun 20239:59 amRNSForm 8.3 - Advanced Oncotherapy PLC
28th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy PLC
27th Jun 202310:29 amRNSForm 8.3 - Advanced Oncotherapy
27th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy
26th Jun 20234:26 pmRNSForm 8.3 - Advanced Oncotherapy
26th Jun 202310:57 amRNSPartial conversion of Convertible Notes
23rd Jun 202311:05 amRNSHolding(s) in Company
23rd Jun 20239:30 amRNSForm 8.3 - Advanced Oncotherapy PLC
20th Jun 20235:28 pmRNSHolding(s) in Company
19th Jun 20235:56 pmRNSPartial conversion of Convertible Notes
19th Jun 20231:48 pmRNSForm 8.3 - Advanced Oncotherapy PLC
16th Jun 20236:23 pmRNSIssue of warrants
13th Jun 202311:46 amRNSForm 8.3 - Advanced Oncotherapy PLC
31st May 20235:57 pmRNSUpdate on financing and convertible notes
30th May 202310:42 amRNSForm 8.3 - Advanced Oncotherapy Plc
24th May 20235:54 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
24th May 20235:29 pmRNSForm 8.3 - Advanced Oncotherapy - Cosylab d.d.
22nd May 20232:59 pmRNSForm 8.3 - Advanced Oncotherapy plc
19th May 202312:09 pmRNSForm 8.3 - Advanced Oncotherapy PLC
17th May 20232:58 pmRNSForm 8.3 - Advanced Oncotherapy plc
15th May 202311:36 amRNSUpdate on Convertible Note & Loan Extension
15th May 20239:19 amRNSForm 8.3 - Advanced Oncotherapy Plc
12th May 202312:53 pmRNSForm 8.3 - Advanced Oncotherapy - Minmetco Limited
11th May 20235:14 pmRNSForm 8.3 - Advanced Oncotherapy - eQ Blue Planet
11th May 202311:17 amRNSForm 8.3 - Advanced Oncotherapy - Atlantic Cedar
10th May 202311:34 amRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:40 pmRNSForm 8.3 - Advanced Oncotherapy - Baltisches Haus
9th May 20234:37 pmRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:36 pmRNSForm 8.3 - Advanced Oncotherapy plc
5th May 20238:56 amRNSFORM 8.3 - Advanced Oncotherapy
5th May 20237:00 amRNSAdditional funding from Secured Convertible Note
4th May 20235:01 pmRNSForm 8.3 - Advanced Oncotherapy Plc
4th May 20233:55 pmRNSChange of Registered Office
3rd May 20236:19 pmRNSRule 2.9 Announcement
3rd May 20234:28 pmRNSForm 8.3 - Advanced Oncotherapy PLC
2nd May 20236:19 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
18th Apr 20237:00 amRNSStrategic review and formal sale process
31st Mar 20236:05 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.